WCM Investment Management LLC Decreases Stake in Insmed Incorporated (NASDAQ:INSM)

WCM Investment Management LLC lessened its position in shares of Insmed Incorporated (NASDAQ:INSM) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 144,740 shares of the biopharmaceutical company’s stock after selling 3,590 shares during the quarter. WCM Investment Management LLC’s holdings in Insmed were worth $9,968,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in INSM. Geode Capital Management LLC boosted its position in shares of Insmed by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after acquiring an additional 172,664 shares during the last quarter. Principal Financial Group Inc. lifted its position in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Insmed by 10.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,444,266 shares of the biopharmaceutical company’s stock worth $105,431,000 after buying an additional 137,670 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock worth $70,260,000 after buying an additional 24,025 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently commented on INSM. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday. Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

Insmed Trading Down 1.0 %

INSM opened at $79.95 on Monday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $82.04. The company has a market capitalization of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11. The stock’s fifty day moving average is $72.88 and its two-hundred day moving average is $73.09. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insider Activity

In related news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 401,030 shares of company stock worth $30,993,629. Company insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.